CYRUS’ PLATFORM USES PHYSICS AND AI BASED MODELING WITH DEEP MUTATIONAL SCANNING TO CREATE THERAPEUTICS DERIVED FROM NATURAL PROTEINS
Cyrus was founded out of the protein design laboratory of Prof. David Baker and the Institute of Protein Design at the University of Washington. Cyrus has provided software to over 120 companies, collaborated on novel biologics with over 30 companies, and worked with most of the top 20 global Pharma firms. In 2020 Cyrus began a biochemistry laboratory with extensive deep mutational scanning capabilities to pursue internal programs and partnered programs, and in 2022 Cyrus co-founded the OpenFold protein AI consosrtium with Amazon, Genentech and others. Cyrus is using this platform to pursue diverse indications where optimized, reengineered biologics can provide superior therapeutic efficacy and safety
David Baker is the director of the University of Washington’s Institute for Protein Design
(UW Medicine Photo)
Company Overview
Cyrus is a pre-clinical-stage biotech company combining protein design and screening to create novel biologics for serious unmet medical needs in IgG mediated autoimmune disease, gastrointestinal autoimmune disease, gene therapy, metabolic disorders / weight loss, COVID, and oncology. All of our programs use our laboratory and AI based platform to modify natural proteins to improve efficacy and optimize liabilities such as half life and immunogenicity
Sign up for our email list: